We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Bernstein analyst William Pickering maintained a Hold rating on Arrowhead Pharmaceuticals on August 15 and set a price target of $17.00. The company’s shares closed last Friday at $20.51. Take ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals shares to stretch its cash runway while also inking a share ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Comp ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.